About us

At Humane Genomics, we use a first-principle approach to designing oncolytic viral therapies. With a dedicated team of experts and the guidance of world-class advisors, we aim to revolutionize cancer treatment by leveraging the potential of viruses to selectively target and eradicate cancer cells.

Why Our Viral Therapies Stand Out

We began by asking the question: What are the most important characteristics of an OVT?
And then we designed our therapies to have these characteristics.

  • Unparalleled Safety: By employing both selective infection and selective replication, we ensure that our therapies target only cancer cells, guaranteeing high safety standards.
  • Highly Lytic: Our viruses are highly lytic, ensuring efficient killing of cancer cells.
  • Maximized Therapeutic Window: Our therapies are designed with a low seroprevalence, ensuring an extended therapeutic window without premature neutralization by the body’s immune system.
  • Systemic Delivery: We tackle the challenge of metastasis by employing systemic delivery methods.
  • Cost-Effective Production: Our therapies are not only potent but also designed with manufacturing in mind. 


Our Cutting-Edge Platform

We pride ourselves on our state-of-the-art platform, specifically developed to expedite the design and testing of our oncolytic viruses.

Here’s how it works:

  • Computer-Aided Design: Our proprietary editor allows for:
    • Utilization of existing building blocks from our library and literature, combined to create functional DNA.
    • The freedom to design intricate structures tailored to specific needs.
    • A feature to codon (de-)optimize, enhancing or suppressing protein expression as needed.
    • Optimization of the design for synthesis, followed by assembly using synthetic DNA.
  • DNA Synthesis: We collaborate with external services for DNA synthesis, ensuring:
    • Sequence-perfect DNA, paving the way for a high-quality pipeline.
    • Rapid advancements in synthesis capabilities, resulting in longer fragments, larger quantities, and reduced costs.
  • Cell Transfection & Virus Testing:
    • We seamlessly assemble the synthesized fragments to form the complete genome.
    • Cells are then transfected, leading to virus production, which is subsequently tested for efficacy.


The Power of Vesicular Stomatitis Virus

Our therapies are based on Vesicular Stomatitis Virus (VSV) due to its many advantages:

  • Linear Genome: This simplifies engineering of the viral genome.
  • Ease of Retargeting: The VSV virus can be modified to target specific cancer cells, by changing the glycoprotein.
  • Highly Lytic Nature: Ensures fast and effective killing of cancer cells.
  • Well-Researched: The VSV virus is well-understood, thanks to extensive research.
  • Low Seroprevalence: Minimizes the risk of the body’s immune system neutralizing the therapy prematurely.

Join us as we pave the way for a new era in cancer treatment.